Transcriptome Analysis of the Peripheral Blood in CIDP

Study Overview
=================
Brief Summary
-----------------
Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is an immune-mediated disorder of peripheral nerves. Intravenous immunoglobulins (IVIg) are a first line therapy for CIDP. The investigators used a transcriptomic approach to compare the gene expression profiles in the peripheral blood of patients having a CIDP or autoimmune diseases, before and after IVIg treatment, in order to identify their mechanism of action in this condition, to lead to a better understanding of CIDP pathophysiology, and potentially determine factors associated with the response to the treatment.

Detailed Description
-----------------
We study the change of the: gene profile on transcriptome analysis of peripheral blood T cell repertory igG dosage immunological profile Before IVIG (T1 time) and and 3 weeks after IVIg treatment (T2 time). On a population of patients having: CIDP, autoimmune muscular disease, Clarkson syndrome, or autoimmune diseases. We also search for polymorphism of FCgammareceptor, TKPC et CASP3 genes in CIDP patients

Official Title
-----------------
Identification of the Mechanisms of Action of Intravenous Immunoglobulins in CIDP by Analysis of the Genetic Expression Profile in Blood Mononuclear Cells

Conditions
-----------------
Chronic Inflammatory Demyelinating Polyradiculoneuropathy, Autoimmune Diseases, Clarkson Syndrome, Muscular Autoimmune Disorders

Intervention / Treatment
-----------------
* Drug: IVIg


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria : Age ≥ 18 years old Obtained informed consent Patient having a definite or probable CIDP according to EFNS/PNS criteria or atypical CIDP corresponding to patients having the EFNS/PNS clinical criteria and at least two EFNS/PNS supportive criteria Or Patient having a muscular autoimmune disease, or a Clarkson syndrome or other autoimmune disease Currently treated by IVIG Exclusion criteria : pregnancy breastfeeding

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: IVIg<br> | Drug: IVIg<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Gene expression profile | Change of the gene expression profile of a peripheral blood sample collected. just before IVIg administration (T1), and 3 weeks after IVIg treatment (T2) | 3 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Gene expression profile in each lymphocytary sub-group | Change of the gene expression profile of a peripheral blood sample collected. just before IVIg administration (T1), and 3 weeks after IVIg treatment (T2), in each lymphocytary sub-group : CD3+CD4+, CD3+CD8+, CD4+FoxP3+, CD4+CD25+ | 3 weeks | 
| IgG | To measure IgG in a peripheral blood sample at T1 and T2 time | 3 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Transcriptome analysis, peripheral blood, chronic inflammatory demyelinating polyradiculoneuropathy, auto immune diseases, IVIg